Media

Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada

MIPS advances to Nasdaq Stockholms Mid Cap segment

Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion

Orexo regains rights to Zubsolv® in all countries outside the US

National Institute for Health and Care Excellence (NICE) issues new guidelines for COPD, Recommending severe patients be evaluated for bronchoscopic lung volume reduction

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Orexo hosts Capital Markets Day today in Stockholm, Sweden

CERENIS announces the results of TANGO, a Phase III clinical study evaluating CER-001 in patients with HDL deficiency